Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. [electronic resource]

By: Contributor(s): Producer: 20131119Description: 1945-6.e1 p. digitalISSN:
  • 1549-4713
Subject(s): Online resources: In: Ophthalmology vol. 120
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

There are no comments on this title.

to post a comment.